Physician profile
Diane De Vos-Schmidt
NPI 1790176543
$2,324.88
in general payments reported to CMS, 2019-2025
36 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Community Health (Nurse Practitioner) provider received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,014 · 2022: $612 · 2023: $176 · 2024: $329 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.75 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.29 | 2021-2025 | |
| Astellas Pharma US INC | $221.48 | 2021-2024 | Padcev, Xtandi |
| Sanofi-Aventis U.S. LLC | $176.94 | 2021 | |
| Travere Therapeutics, INC. | $146.50 | 2024 | |
| Glaxosmithkline, LLC. | $122.71 | 2021 | |
| Fresenius USA Marketing, INC. | $116.80 | 2022 | |
| Ardelyx, INC. | $116.29 | 2025 | Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $102.82 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $101.57 | 2022-2023 | Imbruvica, Epkinly |
| Eisai INC. | $98.41 | 2021-2022 | |
| Secura Bio, INC. | $92.60 | 2021 | |
| Daiichi Sankyo INC. | $70.29 | 2021 | |
| Genzyme Corporation | $68.99 | 2021 | |
| Merck Sharp & Dohme LLC | $64.49 | 2021 | |
| Janssen Biotech, INC. | $62.79 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.86 | 2021-2022 | |
| Pfizer INC. | $35.74 | 2021-2022 | |
| Puma Biotechnology, INC. | $34.24 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $33.81 | 2021-2024 | Farxiga |
| Seagen INC. | $33.18 | 2022 | |
| Acrotech Biopharma INC. | $29.83 | 2021-2022 | |
| Kite Pharma, INC. | $27.35 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $21.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.81 | 2021 | |
| Vifor Pharma, INC. | $20.52 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.56 | 2022 | |
| Emd Serono, INC. | $19.51 | 2021 | |
| Kyowa Kirin, INC. | $19.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.02 | 2021 | |
| Amag Pharmaceuticals, INC. | $18.90 | 2022 | |
| Dova Pharmaceuticals | $17.37 | 2021 | |
| Akebia Therapeutics INC | $15.81 | 2024 | Vafseo, Auryxia |
| Lilly USA, LLC | $15.24 | 2021 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $13.57 | 2022 | |
| Array Biopharma INC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane De Vos-Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.